| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Acorafloxacin HCl targets bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for bacterial DNA replication, transcription, and repair. As a fluoroquinolone, it inhibits these enzymes by stabilizing the DNA-enzyme cleavage complex, leading to DNA double-strand breaks and bacterial cell death. The compound's broad-spectrum activity is characteristic of the fluoroquinolone class. Detailed target selectivity data are not publicly available.
|
|---|---|
| ln Vitro |
Acorafloxacin HCl is a novel, potent, broad-spectrum antibacterial drug. As a fluoroquinolone antibiotic, it is expected to show potent activity against a range of Gram-positive and Gram-negative bacteria. Detailed in vitro data including MIC values against specific bacterial strains are not publicly available. The compound has been studied as a potential treatment for bacterial infections.
|
| ln Vivo |
Not available; detailed in vivo efficacy data for Acorafloxacin HCl are limited. The compound has been studied as a broad-spectrum antibacterial agent.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing using broth microdilution or agar dilution methods to determine minimum inhibitory concentration (MIC) against a range of bacterial strains (Gram-positive and Gram-negative). Bacterial cultures are grown to logarithmic phase, diluted to standard inoculum density, and incubated with serial dilutions of Acorafloxacin HCl at 37°C for 18-24 hours. MIC is determined as the lowest concentration inhibiting visible bacterial growth. DNA gyrase and topoisomerase IV inhibition assays may be performed using recombinant enzymes.
|
| Cell Assay |
In vitro cell-based assays using eukaryotic cell lines to assess cytotoxicity and selectivity. Cells are treated with Acorafloxacin HCl at various concentrations (typically 0.1-100 µM) for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. The selectivity index (SI) is calculated by comparing IC50 values in eukaryotic cells with MIC values in bacteria.
|
| Animal Protocol |
In vivo studies in animal models of bacterial infection (e.g., murine thigh infection model, sepsis model, pneumonia model). Acorafloxacin HCl is administered via various routes (p.o., i.p., i.v., or s.c.) at doses determined from preliminary pharmacokinetic studies. Bacterial burden in tissues is measured by CFU counting. Survival rates are monitored. Pharmacokinetic parameters including oral bioavailability, half-life, and tissue distribution are determined following administration.
|
| References |
|
| Molecular Formula |
C21H24CLF2N3O4
|
|---|---|
| Molecular Weight |
455.88
|
| Exact Mass |
455.142
|
| CAS # |
1001162-01-1
|
| Related CAS # |
878592-87-1;1001162-01-1 (HCl);1160946-14-4 (TFA);
|
| PubChem CID |
67311433
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.532
|
| tPSA |
97.79
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
782
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C2C(=CC(=C1N3CCC/C(=C(/CN)\F)/C3)F)C(=O)C(=CN2C4CC4)C(=O)O.Cl
|
| InChi Key |
RDXCNSOGHLLWDV-YFMOEUEHSA-N
|
| InChi Code |
InChI=1S/C21H23F2N3O4.ClH/c1-30-20-17-13(19(27)14(21(28)29)10-26(17)12-4-5-12)7-15(22)18(20)25-6-2-3-11(9-25)16(23)8-24/h7,10,12H,2-6,8-9,24H2,1H3,(H,28,29)1H/b16-11+
|
| Chemical Name |
(E)-7-(3-(2-amino-1-fluoroethylidene)piperidin-1-yl)-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
|
| Synonyms |
Acorafloxacin HCl Acorafloxacin hydrochloride JNJ-Q2 HCl JNJ 32729463 JNJ32729463JNJ-32729463 Acorafloxacin JNJ-Q2 hydrochlorideJNJ-Q2Avarofloxacin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1936 mL | 10.9678 mL | 21.9356 mL | |
| 5 mM | 0.4387 mL | 2.1936 mL | 4.3871 mL | |
| 10 mM | 0.2194 mL | 1.0968 mL | 2.1936 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.